Insider plans 495860-share Rule 144 sale at Royalty Pharma (NASDAQ: RPRX)

Rhea-AI Filing Summary

Royalty Pharma has a planned Rule 144 sale of 495860 shares of common stock through Goldman Sachs & Co. LLC, with an aggregate market value of 20523645.4 and 427247489 shares outstanding. The shares are expected to be sold on or about 01/07/2026 on NASD. They were originally acquired from the issuer in a private transaction on 06/16/2020, with 495860 shares received on that date.

Over the past 3 months, the person for whose account the securities are to be sold and related entities have already sold multiple blocks of common stock, including 3000 shares on 11/19/2025 for gross proceeds of 113364 and 110000 shares on 12/03/2025 for 4375008. Additional sales by entities such as GWL 2014 G LLC, GWL 2020 G LLC, GWL 2023 G HoldCo LLC, and GWL 2021 G LLC are also listed, reflecting an ongoing disposition program.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Goldman Sachs & Co. LLC 200 West Street New York NY 10282	495860	20523645.4	427247489	01/07/2026	NASD

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	06/16/2020	Acquired from issuer in private transaction	Issuer			495860	06/16/2020	None

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
George Lloyd 110 East 59th Street New York NY 10022	Common Stock	11/19/2025	3000	113364
GWL 2014 G LLC 110 East 59th Street New York NY 10022	Common Stock	12/03/2025	110000	4375008
GWL 2014 G LLC 110 East 59th Street New York NY 10022	Common Stock	12/17/2025	79346	3060280
GWL 2020 G LLC 110 East 59th Street New York NY 10022	Common Stock	11/19/2025	52000	2015410.8
GWL 2023 G HoldCo LLC 110 East 59th Street New York NY 10022	Common Stock	11/19/2025	52426	1991233.85
GWL 2021 G LLC 110 East 59th Street New York NY 10022	Common Stock	11/19/2025	28000	1072643.6
GWL 2014 G LLC 110 East 59th Street New York NY 10022	Common Stock	12/18/2025	30654	1180053.32

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Royalty Pharma (RPRX) shares are planned to be sold under this Rule 144 notice?

The notice covers the planned sale of 495860 shares of Royalty Pharma common stock, with an aggregate market value listed as 20523645.4.

When were the Royalty Pharma (RPRX) shares being sold under Form 144 originally acquired?

The 495860 common shares were acquired from the issuer in a private transaction on 06/16/2020, with the same acquisition date shown for payment.

Which broker is handling the planned Form 144 sale for Royalty Pharma (RPRX) shares?

The broker listed for the planned sale is Goldman Sachs & Co. LLC, 200 West Street, New York, NY 10282.

What is the approximate date and exchange for the planned Royalty Pharma (RPRX) share sale?

The approximate date of sale is 01/07/2026, and the securities are indicated to be sold on NASD.

How many Royalty Pharma (RPRX) shares are shown as outstanding in this Form 144?

The table lists 427247489 shares of Royalty Pharma common stock as outstanding in connection with this notice.

What prior 3‑month Royalty Pharma (RPRX) stock sales are disclosed for this seller?

Disclosed sales include 3000 shares by George Lloyd on 11/19/2025 for gross proceeds of 113364, and multiple sales by entities such as GWL 2014 G LLC, including 110000 shares on 12/03/2025 for 4375008.

Who are the entities associated with recent Royalty Pharma (RPRX) stock sales in this Form 144?

Recent sales over the past 3 months are attributed to George Lloyd and entities including GWL 2014 G LLC, GWL 2020 G LLC, GWL 2023 G HoldCo LLC, and GWL 2021 G LLC.